BNTX vs IPHA
BioNTech SE and Innate Pharma SA, side by side — 9 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | BNTX | IPHA |
|---|---|---|
| Revenue | €2.9B | €9.0M |
| Net income | €-1.1B | €-49.2M |
| Gross margin | 77.6% | · |
| Net margin | −39.6% | −546.1% |
| Return on equity | −5.9% | · |
| Diluted EPS | −€4.70 | −€0.55 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | €280.9M | €-52.9M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 7.54× | 1.27× |
| Revenue CAGR 5y | 42.9% | −33.6% |
| Profit CAGR 5y | · | · |
BNTX bills 318.7× the revenue of IPHA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
9 years side by side
| Fiscal year | BNTX | IPHA |
|---|---|---|
| FY2025 | €2.9B | €9.0M |
| FY2024 | €2.8B | €20.1M |
| FY2023 | €3.8B | €61.6M |
| FY2022 | €17.3B | €57.7M |
| FY2021 | €19.0B | €24.7M |
| FY2020 | €482.3M | €69.8M |
| FY2019 | €108.6M | €85.4M |
| FY2018 | €127.6M | €94.0M |
| FY2017 | €61.6M | €44.0M |
Bottom line
| Fiscal year | BNTX | IPHA |
|---|---|---|
| FY2025 | €-1.1B | €-49.2M |
| FY2024 | €-665.3M | €-49.5M |
| FY2023 | €930.3M | €-7.6M |
| FY2022 | €9.4B | €-58.1M |
| FY2021 | €10.3B | €-52.8M |
| FY2020 | €15.2M | €-64.0M |
| FY2019 | €-179.1M | €-20.8M |
| FY2018 | €-48.0M | €3.0M |
| FY2017 | €-85.7M | €-48.4M |
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +€2,860,895,000 | BNTX |
| FY2024 | +€2,730,979,000 | BNTX |
| FY2023 | +€3,757,359,000 | BNTX |
| FY2022 | +€17,252,926,000 | BNTX |
| FY2021 | +€18,951,997,000 | BNTX |
| FY2020 | +€412,527,000 | BNTX |
| FY2019 | +€23,151,000 | BNTX |
| FY2018 | +€33,623,000 | BNTX |
| FY2017 | +€17,565,000 | BNTX |
BNTX has reported the higher revenue in every one of these 9 fiscal years. The gap has widened since the earliest year compared.
9 of 9 comparable fiscal years — a year missing data on either side is not counted.
8 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +506.5 pp | BNTX |
| FY2024 | +221.7 pp | BNTX |
| FY2023 | +36.6 pp | BNTX |
| FY2022 | +155.2 pp | BNTX |
| FY2020 | +94.9 pp | BNTX |
| FY2019 | −140.7 pp | IPHA |
| FY2018 | −41.1 pp | IPHA |
| FY2017 | −29.7 pp | IPHA |
The higher net margin has changed hands between BNTX and IPHA over this period.
8 of 9 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
IPHA's net margin has been more volatile than BNTX's over the 8 comparable fiscal years — 170.0 percentage points of standard deviation against 71.3.
8 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between BNTX and IPHA over these 8 fiscal years — BNTX led in 5 and IPHA in 3.
8 of 9 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BNTX's return on equity has been more volatile than IPHA's over the 6 comparable fiscal years — 64.6 percentage points of standard deviation against 51.9.
6 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between BNTX and IPHA over these 6 fiscal years — BNTX led in 5 and IPHA in 1.
6 of 9 comparable fiscal years — a year missing data on either side is not counted.